Recent Company News

• 09:02 PM ET Jun 21, 2025
  

  Long Term Trading Analysis for (RDHL)

• 07:11 AM ET May 13, 2025
  

  RedHill awarded attachment petition to the Court in South Korea on Kukbo Co. Ltd's ("Kukbo") assets ($2.00, 0.00)

• 07:00 AM ET May 13, 2025
  

  RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

• 02:15 AM ET May 09, 2025
  

  (RDHL) On The My Stocks Page

• 07:06 AM ET Apr 28, 2025
  

  RedHill Biopharma secures allowance of Chinese patent application for RHB-107 ($2.41, 0.00)

• 07:03 AM ET Apr 16, 2025
  

  RedHill Biopharma announced the new publication of in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity ($2.14, 0.00)

• 07:51 AM ET Apr 10, 2025
  

  RedHill Biopharma reports FY net income ($8.3M) vs year-ago $23.9M ($2.70, 0.00)

• 07:01 AM ET Mar 18, 2025
  

  RedHill Biopharma to submit FDA-approved Talicia for UK marketing authorisation ($3.01, 0.00)

• 07:11 AM ET Mar 12, 2025
  

  RedHill plans to initiate Phase 2 study of RHB-204 in Mycobacterium avium subspecies paratuberculosis-positive (MAP+) moderate to severe CD ($2.79, 0.00)

• 07:15 AM ET Feb 27, 2025
  

  RedHill Biopharma presents business update at the Sachs' European Life Sciences CEO Forum ($3.85, 0.00)